TTP Group continues growth course
17 February 2021
©UCB Farchim SA, Bulle Switzerland
©UCB Farchim SA, Bulle Switzerland
TTP Group with Triplan active in four countries
“The Europe-wide growth strategy of the TTP Group is reflected in a further strengthening of the market presence in the entire DACH region”, says Andreas Bonhoff, CEO of the TTP Group.
Both Triplan and Pharmaplan are expanding their already close cooperation with customers at these two important chemical and pharmaceutical locations.
Pharmaplan with another location in Entzheim, France
Another location is from theFrench TTP subsidiary Pharmaplan S.A. opened in February in Entzheim, France. For Arnaud Eber, the Pharmaplan Managing Director in France and Belgium, the new location corresponds to the philosophy of the group of companies, which focuses on proximity to customers and partners:
“With the two Pharmaplan sites in Entzheim and Lyon, we are now closer to the pharma and biotech players in the Grand Est region, one of the most important areas in France for pharmaceutical and biotechnological production. In this way, we can strengthen existing collaborations with some important customers in the region, such as Lilly, Octapharma and Novartis, but also develop new partnerships with other pharmaceutical and biotech companies in the Alsatian cluster.”
Overall, the four French Pharmaplan sites in Paris, Lyon, Chartres and Entzheim cover Pharmaplan’s entire service portfolio: front-end studies, general planning (EPCMV), site projects and premium consulting in the areas of GMP, quality, process, clean room, Automation and digitization. More Pharmaplan locations are opening in Switzerland planned. As one of the leading pharmaceutical engineering companies in Europe, Pharmaplan is shaping the future of the industry. With the planning and construction of modern pharmaceutical production sites, excellent employees from the fields of architecture, engineering and natural sciences set the course for the global supply of medicines of tomorrow.
